Afuco™ Anti-Human GM2 ADCC Recombinant Antibody (BIW-8962), ADCC Enhanced (CAT#: AFC-307CL)

Anti-GM2 ADCC Enhanced Antibody (BIW-8962) is an ADCC enhanced antibody produced by our Afuco™ platform. BIW-8962 is a humanized anti-ganglioside GM2 (GM2) monoclonal antibody, exhibited a potent ADCC and less potent CDC activity. Currently BIW-8962 is being investigated in a Phase 1 study in patients with multiple myeloma.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 To determine the mode of action of these anti-GM2 antibodies, we histologically analyzed liver metastases treated with PBS (control) or anti-GM2 antibodies.

Figure 1 To determine the mode of action of these anti-GM2 antibodies, we histologically analyzed liver metastases treated with PBS (control) or anti-GM2 antibodies.

Histological examination of metastatic lesions treated with anti-ganglioside GM2 antibodies. SBC-3 (1 × 10⁶) small-cell lung cancer cells were inoculated i.v. into natural killer cell-depleted SCID mice. The mice were injected with PBS, control IgG, KM966, BIW-8962, or KM8927, on days 7, 14, 21, 28, and 35 and killed on day 42. Metastatic liver lesions were harvested and stained with H&E, and for Ki-67, an indicator of cell proliferation, TUNEL, an indicator of cell apoptosis, and GM2 expression. (A) Microscopic appearance of lesions. (B) Quantification of the percentage of Ki-67-positive cancer cells and (C) the number of TUNEL-positive apoptotic cells. Data shown are the mean ± SD of five independent areas. Results shown are representative of at least two independent experiments. HPF, high power field. *P < 0.05 compared with control.

Yamada,T.,Bando,H.,Takeuchi,S.,Kita,K.,Li,Q.,Wang,W.,& Yano, S.(2011).Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer science, 102(12), 2157-2163.

Figure 2 treatment with these mAbs dramatically prolonged survival of the mice compared with control.

Figure 2 treatment with these mAbs dramatically prolonged survival of the mice compared with control.

Effect of anti-ganglioside GM2 antibodies on survival of SBC-3-bearing mice. SBC-3 (1 × 10⁶) small-cell lung cancer cells were inoculated i.v. into natural killer cell-depleted SCID mice. The mice (10 per group) were treated with PBS, control IgG, KM966, BIW-8962, or KM8927, once a week starting on day 7. Results shown are representative of two independent experiments. *P < 0.001 compared with control.

Yamada,T.,Bando,H.,Takeuchi,S.,Kita,K.,Li,Q.,Wang,W.,& Yano, S.(2011).Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer science, 102(12), 2157-2163.

Figure 3 GM2 expression in MPM cell lines.

Figure 3 GM2 expression in MPM cell lines.

Expression levels of ganglioside GM2 were evaluated in malignant pleural mesothelioma cell lines. Cells were detached and incubated with BIW-8962 or anti-dinitrophenol (DNP) antibodies on ice for 30 min. Bound Abs were detected with FITC-conjugated goat anti-human IgG Abs. The fluorescence intensity of the stained cells was measured using flow cytometry, and the mean fluorescence intensity was calculated. The open red histograms represent BIW-8962-stained samples and the filled blue histograms represent anti-DNP antibody-stained samples. The relative fluorescent intensity (RFI) versus anti-DNP is indicated.

Li,Q.,Wang,W.,Machino,Y.,Yamada T.,Kita,K.,Oshima,M.,& Iida, S. (2015). Therapeutic activity of glycoengineered anti-GM 2 antibodies against malignant pleural mesothelioma. Cancer science, 106(1), 102-107.

Figure 4 Antibody-dependent cellular cytotoxicity activity against MPM cell line.

Figure 4 Antibody-dependent cellular cytotoxicity activity against MPM cell line.

Anti-GM2 antibody BIW-8962 exerted antibody-dependent cellular cytotoxicity activity against MSTO-211H malignant pleural mesothelioma cells. Human peripheral blood mononuclear cells were purified from healthy donors and used as effector cells. MSTO-211H cells (target cells) were incubated with effector cells (effector/target = 25/1, 50/1, and 100/1) and antibodies (BIW-8962 or anti-dinitrophenol antibodies) at 37°C for 4 h. The released lactate dehydrogenase activity was measured and the % cytotoxicity was calculated. The experiments were carried out in triplicate, and the values are expressed as the mean of the values for four donors ± SD. *P < 0.01, **P < 0.001 BIW-8962 treatment versus anti-dinitrophenol antibody treatment.

Li,Q.,Wang,W.,Machino,Y.,Yamada T.,Kita,K.,Oshima,M.,& Iida, S. (2015). Therapeutic activity of glycoengineered anti-GM 2 antibodies against malignant pleural mesothelioma. Cancer science, 106(1), 102-107.

Figure 5 In vivo therapeutic activity of BIW-8962 in orthotropic mouse model.

Figure 5 In vivo therapeutic activity of BIW-8962 in orthotropic mouse model.

Anti-GM2 antibody BIW-8962 showed therapeutic activity in an MSTO-211H orthotropic mouse model. MSTO-211H malignant pleural mesothelioma cells were inoculated into the thoracic cavity in SCID mice, and the animals were treated with BIW-8962 and/or human peripheral blood mononuclear cells (MNC). The mice were then i.v. administered BIW-8962 and/or MNC on days 7 and 14. At 3 weeks after tumor cell inoculation, the mice were sacrificed and their tumor weights were measured. The bars represent the mean of the group data. *P < 0.05 and **P < 0.01 between each treatment and the control groups.

Li,Q.,Wang,W.,Machino,Y.,Yamada T.,Kita,K.,Oshima,M.,& Iida, S. (2015). Therapeutic activity of glycoengineered anti-GM 2 antibodies against malignant pleural mesothelioma. Cancer science, 106(1), 102-107.


Specifications

  • Host Species
  • Humanized
  • Derivation
  • Humanized
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Related Disease
  • Multiple Myeloma

Product Property

  • Purity
  • >95% as judged by SDS-polyacrylamide gel electrophoresis
  • Storage
  • Store at -20°C. Open under aseptic conditions.

Target

  • Alternative Names
  • GM2; GM2 Ganglioside

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "GM2"

Recombinant Antibody

Humanized Antibody

CAT Product Name Application Type
TAB-320CL Anti-Human GM2 Recombinant Antibody (BIW-8962) FC, FuncS, IF Antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-307CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare